Sign up USA
Proactive Investors - Run By Investors For Investors

Pressure Biosciences increases revenue and gross margins in first quarter

Total revenue came in at $551,357 for the three months to March 31, compared to $510,478 during the same period of 2016
Pressure Biosciences increases revenue and gross margins in first quarter
Pressure Biosciences makes ....

Sales of products and services helped boost revenues in the first quarter, said Pressure Biosciences Inc (OTCMKTS:BIO), positioning it well for growth in the rest of fiscal 2017.

The life sciences group develops, markets, and sells proprietary laboratory instrumentation and associated consumables to the estimated $6bn sample preparation market

Total revenue came in at $551,357 for the three months to March 31, compared to $510,478 during the same period of 2016, despite a decrease in grant revenue.

Products and services revenue increased 16% to $525,998, mainly due to a 19% increase in instrument systems sales.

Sales of consumables also increased 43% to $63,264 in the quarter.

The operating loss decreased 4% to $999,103 from $1,045,945 for the same quarter of 2016.

Joseph L. Damasio, chief financial officer, said: "As reported, we continued to show quarter-over-quarter revenue growth, especially in the important area of products and services.

"We also increased gross margins during the period. What makes these accomplishments even more rewarding was their achievement during a quarter in which we were also able to reduce operating expenses and operating loss.

"We believe the financial results of the first quarter 2017 have set us up well to significantly drive revenue and business growth for the rest of the fiscal 2017 year, and beyond."

Richard T. Schumacher, president and chief executive, added: "Although pleased with the financial results of the first quarter, we are even more pleased with our operational accomplishments."

Included in these, in February, it achieved CE Marking for its Barocycler 2320EXT, the next-generation PCT-based sample preparation instrument.

Pressure can now market and sell the device in all 31 countries in the European Economic Area.

Meanwhile, in March, it significantly bolstered its sales capabilities by contracting with lead generating firm EKG Sales Associates, and by hiring two of its planned four field sales directors.

Shares lost 5.82% on the day.. 

View full PBIO profile View Profile

Pressure BioSciences Inc Timeline

Related Articles

Workers at CERN
August 02 2018
Private banks and healthcare groups took part in the share placing
picture of addict
November 15 2017
To build the UK's first £1bn, self-sustainable biotech is the aim for chief executive Clive Dix
scientist looking through microscope
April 11 2018
Kumaraguru Raja sees “multiple catalysts” in the year ahead which could put a rocket under the share price

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright ©, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use